Systemic Manifestations and Mortality Risk in Transthyretin V142I Variant Carriers: A Million
Dre Hanane Benbarkat - Cardiologue - Hôpital Maisonneuve Rosemont, Montréal Systemic Manifestations and Mortality Risk in Transthyretin V142I Variant Carriers: A Million Veteran Program Analysis. https://pubmed.ncbi.nlm.nih.gov/41705... Modérateurs : Dre Kim O'Connor - Cardiologue - ICPQ, Québec Valérie Fontaine IPS - Cardiologue - CHUM Montréal Dr François TOURNOUX - Cardiologue - CHUM de Montréal
▶︎
Bibliose 26 mars 2026
▶︎
Proteomics Profiling Reveals Circulating Biomarkers and Dysregulated Pathways in Transthyretin Amylo
▶︎
The CATCH ATTR study CArpal Tunnel ligament amyloid the Clue for early identification of Hereditary
▶︎
What do tech pioneers think about the AI revolution? - The Engineers, BBC World Service
▶︎
Webinar – Latest developments on the PFAS restriction proposal
▶︎
Prevalence and Prognostic Significance of Restriction Versus Systolic Dysfunction in Patients With T
▶︎
UN Medical Insurance Plan en français 20260611 120042UTC Meeting Recording
▶︎
Rendez-vous digital "Péri-habilitation en oncogériatrie" OncoPaca-Corse, UCOG Paca-Ouest et Paca-Est
▶︎
If You Have A Bad Memory, I’ll Help You Fix It In 28 Minutes
▶︎
ADD/ADHD | What Is Attention Deficit Hyperactivity Disorder?
▶︎
Development and Validation of a Risk Score for Transthyretin Amyloidosis in Patients with Severe Aor
▶︎
Nervous System Regulation (999 Hz) | 1 hour handpan music | Malte Marten
▶︎
Antineoplastic Agents | Clinical Medicine
▶︎
Transthyretin amyloid cardiomyopathy natural history and treatment response assessed by cardiovas...
▶︎
It's NOT Memory - 5 Early Dementia Signs Everyone Misses
▶︎
How to Invest As a Teen With $0
▶︎
New garage concrete
▶︎
Atrial Mechanical Contraction Predicts Cerebrovascular Risk in Patients With Transthyretin Amyloid
▶︎
Introduction to Suture
▶︎